Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picks3i Group Regulatory News (III)

Share Price Information for 3i Group (III)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2,845.00
Bid: 2,843.00
Ask: 2,845.00
Change: -31.00 (-1.08%)
Spread: 2.00 (0.07%)
Open: 2,881.00
High: 2,881.00
Low: 2,835.00
Prev. Close: 2,876.00
III Live PriceLast checked at -
3i Group is an Investment Trust

To provide its shareholders with quoted access to private equity and infrastructure returns, its main focus is on making quoted and unquoted equity and/ or debt investments in businesses and funds in Europe, Asia and the Americas.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Covid-19 update and Action Seminar

19 Mar 2020 08:30

RNS Number : 7254G
3i Group PLC
19 March 2020
 

Press release

19 March 2020

 

3i Group plc

Update on Covid-19 andAction Capital Markets Seminar

 

3i Group plc ("3i" or "the Group") will be holding a Capital Markets Seminar this morning, involving a presentation from the management team of Action. Presentation materials will be made available on 3i's website (www.3i.com), and a copy of the transcript will be published when it is available.

Since 3i published its performance update for the nine months to 31 December 2019 on 30 January 2020, the global impact of Covid-19 on public health, business, financial markets, and governments' responses has developed rapidly. This further update provides a brief summary of the current status of 3i's balance sheet position and our Private Equity portfolio ahead of the valuation of the portfolio as at 31 March 2020.

3i Group balance sheet

3i has had a conservative balance sheet strategy since its restructuring in 2012. It has two long-dated bonds (£200 million, maturing in 2023, and £375 million, maturing in 2032) which have no financial covenants. On 13 March 2020, we completed the refinancing of our Revolving Credit Facility ("RCF"), increasing its amount from £350 million to £400 million in a five year facility with an option to extend annually for a further two years. The cost of the facility, which has no financial covenants, was also reduced. At 31 March 2020, we expect our cash balance to be c.£800 million before the payment of carry in respect of the Action liquidity event due in May 2020; there are currently no plans to draw on our RCF.

Private Equity portfolio

We completed our semi-annual portfolio company review meetings of the substantial majority of our top 20 investments (which at 31 December accounted for 97% of the total Private Equity portfolio value) in the week commencing 9 March 2020. Although the situation is very fluid, the majority of our portfolio is expected to experience a modest short-term disruption to its business, principally as a result of the country by country lockdowns. A small number of other companies are more directly and significantly affected, at least in the short term. These include Action, BoConcept and Hans Anders in the retail sector, and Audley Travel and ICE in the travel sector. Basic-Fit, in which we have a 13% stake, has also seen a significant decline in its share price.

An update on Action's performance for 2019, and the current status of the impact of Covid-19 on the business will be provided at the seminar this morning.

More generally, we are focused on working with our portfolio companies to support them through these unprecedented times. The weighted average net debt of the portfolio at 31 December 2019 was 4.0x excluding Action.

Private Equity investments and realisations

We invested £471 million in the nine months to 31 December 2019, including new investments in Magnitude Software, Evernex, and the new bioprocessing platform. We have recently seen a number of new investment processes being postponed in light of the current environment. We are focusing our efforts on supporting our portfolio companies to deal effectively with the Covid-19 situation.

On 5 December 2019, we announced the signing of an implementation agreement to dispose of our investment in ACR. We received final approvals to complete this transaction. Proceeds are subject to a number escrow arrangements; we expect to receive the first tranche of c.$136 million in Q3 2020.

We have also signed an agreement to sell another portfolio company for proceeds of up to €96 million, which will be announced in due course and is expected to complete later this year.

Portfolio valuation at 31 March 2020

For some time, we have had a policy of taking a longer-term approach to the multiples used to value our portfolio. This has meant that, in recent years, we have typically used multiples lower than those prevailing for comparable quoted companies. As a result, we have been able to mitigate the impact of market volatility in the past. Although the valuation of our portfolio will depend on market multiples and outlook as at 31 March 2020, the significant and continuing falls in equity markets will put more pressure on the multiples that we will use to value the portfolio as at that date, particularly for those portfolio companies currently most directly exposed to the impact of Covid-19.

 

- Ends-

 

 

For further information, contact:

 

3i Group plc

 

Silvia Santoro

Investor enquiries

 

Kathryn van der Kroft

Media enquiries

 

 

 

Tel: +44 20 7975 3258

Email: silvia.santoro@3i.com

 

Tel: +44 20 7975 3021

Email: kathryn.vanderkroft@3i.com

 

 

 

Notes to editors:

 

About 3i Group

 

3i is a leading international investment manager focused on mid-market Private Equity and Infrastructure. Our core investment markets are northern Europe and North America.

 

For further information, please visit: www.3i.com.

 

 

Appendix 1 - Top 20 investments

 

Company

Value at Dec 19

£m

1

Action

3,461

2

3i Infrastructure plc

791

3

Scandlines

464

4

Cirtec Medical

256

5

Hans Anders

249

6

Q Holding Inc

245

7

WP

237

8

Audley Travel

217

9

Evernex

206

10

Aspen Pumps

203

11

Basic Fit

198

12

Smarte Carte

183

13

Havea

180

14

AES

179

15

Formel D

177

16

Royal Sanders

170

17

Regional Rail

163

18

ICE

159

19

Tato

158

20

Boconcept

149

Top 20 by NAV

8,045

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCZZGMFMLRGGZG
Date   Source Headline
31st Oct 20182:34 pmRNSDirector/PDMR Shareholding
24th Oct 20189:14 amRNSDirectorate Change
3rd Oct 201811:48 amRNSPortfolio Update
28th Sep 20182:35 pmRNSTotal Voting Rights
28th Sep 20182:34 pmRNSDirector/PDMR Shareholding
17th Sep 201812:30 pmRNSPrivate Equity Capital Markets Seminar
31st Aug 20183:27 pmRNSDirector/PDMR Shareholding
31st Aug 20183:26 pmRNSTotal Voting Rights
22nd Aug 201812:50 pmRNSDirector Declaration
31st Jul 20184:42 pmRNSTotal Voting Rights
31st Jul 20184:37 pmRNSDirector/PDMR Shareholding
31st Jul 20187:00 amRNS3i announces result of audit tender
27th Jul 201811:13 amRNSDirector/PDMR Shareholding
25th Jul 20182:37 pmRNSDirector/PDMR Shareholding
25th Jul 20187:00 amRNSFY2019 Q1 performance update
18th Jul 201812:02 pmRNSDirector/PDMR Shareholding
10th Jul 201812:32 pmRNSDirector/PDMR Shareholding
4th Jul 201810:30 amRNSPortfolio Update
3rd Jul 20189:48 amRNSDirector/PDMR Shareholding
29th Jun 20183:07 pmRNSTotal Voting Rights
29th Jun 20183:02 pmRNSDirector/PDMR Shareholding
28th Jun 20182:49 pmRNSDirector/PDMR Shareholding
28th Jun 20182:46 pmRNSResult of AGM
28th Jun 20182:45 pmRNSDoc re. AGM Resolutions
26th Jun 20181:37 pmRNSDirector/PDMR Shareholding
12th Jun 20182:51 pmRNSBlock listing Interim Review
12th Jun 201811:28 amRNSDirector/PDMR Shareholding
6th Jun 20182:58 pmRNSDirector/PDMR Shareholding
5th Jun 20183:20 pmRNSDirector/PDMR Shareholding
31st May 20183:36 pmRNSTotal Voting Rights
31st May 20183:33 pmRNSDirector/PDMR Shareholding
29th May 20183:50 pmRNSDTR 6.3.5.
29th May 20183:49 pmRNSDoc re. 2018 Annual Report and Accounts
25th May 201810:32 amRNSDirector Declaration
18th May 20181:29 pmRNSDirector/PDMR Shareholding
18th May 201811:56 amRNSDirector/PDMR Shareholding
17th May 20187:00 amRNSFinal Results
30th Apr 20184:11 pmRNSTotal Voting Rights
30th Apr 20184:07 pmRNSDirector/PDMR Shareholding
4th Apr 201810:11 amRNSPortfolio Update
29th Mar 20182:02 pmRNSTotal Voting Rights
29th Mar 20181:59 pmRNSDirector/PDMR Shareholding
9th Mar 20188:30 amRNSAction refinancing and Capital Markets seminar
28th Feb 20183:44 pmRNSTotal Voting Rights
28th Feb 20183:44 pmRNSDirector/PDMR Shareholding
1st Feb 20183:51 pmRNSDirector/PDMR Shareholding
1st Feb 20187:00 amRNSFY2018 Q3 performance update
31st Jan 20184:17 pmRNSTotal Voting Rights
31st Jan 20184:16 pmRNSDirector/PDMR Shareholding
2nd Jan 20184:15 pmRNSPortfolio Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.